Cargando…

Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes

Current therapies for metastatic clear cell renal cell carcinoma (ccRCC) show limited efficacy. Drug efficacy, typically investigated in preclinical cell line models during drug development, is influenced by pharmacogenes involved in targeting and disposition of drugs. Here we show through genome-wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Winter, Stefan, Fisel, Pascale, Büttner, Florian, Rausch, Steffen, D’Amico, Debora, Hennenlotter, Jörg, Kruck, Stephan, Nies, Anne T., Stenzl, Arnulf, Junker, Kerstin, Scharpf, Marcus, Hofmann, Ute, van der Kuip, Heiko, Fend, Falko, Ott, German, Agaimy, Abbas, Hartmann, Arndt, Bedke, Jens, Schwab, Matthias, Schaeffeler, Elke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951699/ https://www.ncbi.nlm.nih.gov/pubmed/27435027 http://dx.doi.org/10.1038/srep29930

Ejemplares similares

MCT4 surpasses the prognostic relevance of the ancillary protein CD147 in clear cell renal cell carcinoma
por: Fisel, Pascale, et al.
Publicado: (2015)

Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma
por: Büttner, Florian, et al.
Publicado: (2018)

Characterization of Genetic Heterogeneity in Recurrent Metastases of Renal Cell Carcinoma
por: Sauter-Meyerhoff, Carolin, et al.
Publicado: (2021)

Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and Metastases
por: Maas, Moritz, et al.
Publicado: (2023)

Nicotinamide‐N‐methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma
por: Reustle, Anna, et al.
Publicado: (2022)

A Rare Case of Synchronous Renal Cell Carcinoma of the Bladder Presenting With Gross Hematuria
por: Kruck, Stephan, et al.
Publicado: (2013)

Impact of an Altered Wnt1/β-Catenin Expression on Clinicopathology and Prognosis in Clear Cell Renal Cell Carcinoma
por: Kruck, Stephan, et al.
Publicado: (2013)

A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy
por: Büttner, Florian A., et al.
Publicado: (2022)

Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy
por: Reustle, Anna, et al.
Publicado: (2020)

Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy
por: Thaiss, Wolfgang M., et al.
Publicado: (2022)

The prognostic value of fat invasion and tumor expansion in the hilar veins in pT3a renal cell carcinoma
por: Stühler, Viktoria, et al.
Publicado: (2021)

Utility of pT3 substaging in lymph node-negative urothelial carcinoma of the bladder: do pathologic parameters add to prognostic sub-stratification?
por: Maas, Moritz, et al.
Publicado: (2021)

Versatility and clinical effectiveness of a synthetic sealing hemostatic patch as alternative to parenchyma suturing in laparoscopic partial nephrectomy
por: Erne, Eva, et al.
Publicado: (2021)

Checkpoint modulation - A new way to direct the immune system against renal cell carcinoma
por: Bedke, Jens, et al.
Publicado: (2015)

Clinical and Functional Relevance of the Monocarboxylate Transporter Family in Disease Pathophysiology and Drug Therapy
por: Fisel, Pascale, et al.
Publicado: (2018)

Pharmacogene Variation Consortium Gene Introduction: NUDT15
por: Yang, Jun J., et al.
Publicado: (2018)

Economic aspects of bladder cancer: what are the benefits and costs?
por: Sievert, K. D., et al.
Publicado: (2009)

DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma
por: Schaeffeler, Elke, et al.
Publicado: (2011)

Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab
por: Stühler, Viktoria, et al.
Publicado: (2022)

Real world data on IO-based therapy for metastatic renal cell carcinoma
por: Stühler, Viktoria, et al.
Publicado: (2022)

Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases
por: Aufderklamm, Stefan, et al.
Publicado: (2018)

Performance of Urinary Markers for Detection of Upper Tract Urothelial Carcinoma: Is Upper Tract Urine More Accurate than Urine from the Bladder?
por: Bier, Simone, et al.
Publicado: (2018)

Circulating tumor cells and their role in prostate cancer
por: Maas, Moritz, et al.
Publicado: (2019)

Circulating and Disseminated Tumor Cells in the Management of Advanced Prostate Cancer
por: Kruck, Stephan, et al.
Publicado: (2012)

Oncological validation of bone turnover markers c-terminal telopeptide of type I collagen (1CTP) and peptides n-terminal propeptide of type I procollagen (P1NP) in patients with prostate cancer and bone metastases
por: Aufderklamm, Stefan, et al.
Publicado: (2021)

Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer
por: Hegemann, Miriam, et al.
Publicado: (2019)

Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies
por: Stühler, Viktoria, et al.
Publicado: (2022)

Androgen receptor overexpression in prostate cancer in type 2 diabetes
por: Lutz, Stefan Zoltán, et al.
Publicado: (2017)

Is a single portal venous phase in contrast-enhanced CT sufficient to detect metastases or recurrence in clear cell renal cell carcinoma? – a single-center retrospective study
por: Hagen, Florian, et al.
Publicado: (2022)

Assessment of a new point-of-care system for detection of prostate specific antigen
por: Rausch, Steffen, et al.
Publicado: (2016)

Transcript Levels of Aldo-Keto Reductase Family 1 Subfamily C (AKR1C) Are Increased in Prostate Tissue of Patients with Type 2 Diabetes
por: Franko, Andras, et al.
Publicado: (2020)

Increased Expressions of Matrix Metalloproteinases (MMPs) in Prostate Cancer Tissues of Men with Type 2 Diabetes
por: Franko, Andras, et al.
Publicado: (2020)

Pharmacogene regulatory elements: from discovery to applications
por: Smith, Robin P, et al.
Publicado: (2012)

Identification, conservation, and expression of tiered pharmacogenes in zebrafish
por: Demery-Poulos, Catherine, et al.
Publicado: (2022)

Genetic Variation among Pharmacogenes in the Sardinian Population
por: Idda, Maria Laura, et al.
Publicado: (2022)

Urinary Tract Tumor Organoids Reveal Eminent Differences in Drug Sensitivities When Compared to 2-Dimensional Culture Systems
por: Wei, Yi, et al.
Publicado: (2022)

CD24: A Marker for an Extended Expansion Potential of Urothelial Cancer Cell Organoids In Vitro?
por: Geng, Ruizhi, et al.
Publicado: (2022)

T2 mapping for the characterization of prostate lesions
por: Hepp, Tobias, et al.
Publicado: (2022)

Thioredoxin 1 (Trx1) is associated with poor prognosis in clear cell renal cell carcinoma (ccRCC): an example for the crucial role of redox signaling in ccRCC
por: Ribback, Silvia, et al.
Publicado: (2021)

Ontogeny-related pharmacogene changes in the pediatric liver transcriptome
por: Meier, Richard, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hbp7cesmupgdk7vs9ib8tt657g